Pesquisar
Regeneron Pharmaceuticals Inc
REGNAdicionar à lista de desejos
618.030USD
+5.530+0.90%
Fechamento 06/23, 16:00（ET）Cotações atrasadas em 15 min
64.79BValor de mercado
14.55P/L TTM
Mais detalhes de Regeneron Pharmaceuticals Inc Empresa
Regeneron Pharmaceuticals, Inc. is a fully integrated biotechnology company. The Company invents, develops, manufactures, and commercializes medicines for people with serious diseases. Its products and product candidates in development are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neurological diseases, hematologic conditions, infectious diseases, and rare diseases. The Company is accelerating drug development using its proprietary technologies, such as VelociSuite, which produces optimized fully human antibodies and new classes of bispecific antibodies. VelociSuite consists of VelocImmune, VelociGene, VelociMouse, VelociMab, Veloci-Bi, VelociT, VelociHum, and other related technologies. Its marketed products include EYLEA (aflibercept); Dupixent (dupilumab); Libtayo (cemiplimab); Ordspono (odronextamab); Kevzara (sarilumab); Itepekimab; Linvoseltamab, and others.
Informações de Regeneron Pharmaceuticals Inc
Código da empresaREGN
Nome da EmpresaRegeneron Pharmaceuticals Inc
Data de listagemApr 02, 1991
CEOSchleifer (Leonard S)
Número de funcionários15106
Tipo de títulosOrdinary Share
Fim do ano fiscalApr 02
Endereço777 Old Saw Mill River Road
CidadeTARRYTOWN
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal10591
Telefone17813705000
Sitehttps://www.regeneron.com/
Código da empresaREGN
Data de listagemApr 02, 1991
CEOSchleifer (Leonard S)
Executivos da empresa Regeneron Pharmaceuticals Inc
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. George D. Yancopoulos, M.D., Ph.D
Dr. George D. Yancopoulos, M.D., Ph.D
Co-Chairman of the Board, President, Chief Scientific Officer
Co-Chairman of the Board, President, Chief Scientific Officer
1.13M
+0.00%
Dr. Leonard S. Schleifer, M.D., Ph.D
Dr. Leonard S. Schleifer, M.D., Ph.D
Co-Chairman of the Board, President, Chief Executive Officer, Founder
Co-Chairman of the Board, President, Chief Executive Officer, Founder
688.09K
+0.00%
Dr. Andrew J. Murphy, Ph.D.
Dr. Andrew J. Murphy, Ph.D.
Executive Vice President - Research
Executive Vice President - Research
52.21K
+0.06%
Mr. Joseph J. LaRosa
Mr. Joseph J. LaRosa
Executive Vice President, General Counsel, Secretary
Executive Vice President, General Counsel, Secretary
42.31K
-5.98%
Mr. Daniel P. Van Plew
Mr. Daniel P. Van Plew
Executive Vice President, General Manager - Industrial Operations and Product Supply
Executive Vice President, General Manager - Industrial Operations and Product Supply
35.18K
+0.02%
Mr. George L. Sing
Mr. George L. Sing
Independent Director
Independent Director
33.07K
+0.02%
Mr. Christopher R. Fenimore
Mr. Christopher R. Fenimore
Chief Financial Officer, Executive Vice President - Finance
Chief Financial Officer, Executive Vice President - Finance
21.80K
+0.07%
Mr. Arthur F. (Art) Ryan
Mr. Arthur F. (Art) Ryan
Independent Director
Independent Director
17.42K
-0.57%
Ms. Marion E. McCourt
Ms. Marion E. McCourt
Executive Vice President - Commercial
Executive Vice President - Commercial
14.49K
+0.82%
Dr. Michael S. Brown, M.D.
Dr. Michael S. Brown, M.D.
Independent Director
Independent Director
12.78K
+0.04%
Ver Mais
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. George D. Yancopoulos, M.D., Ph.D
Dr. George D. Yancopoulos, M.D., Ph.D
Co-Chairman of the Board, President, Chief Scientific Officer
Co-Chairman of the Board, President, Chief Scientific Officer
1.13M
+0.00%
Dr. Leonard S. Schleifer, M.D., Ph.D
Dr. Leonard S. Schleifer, M.D., Ph.D
Co-Chairman of the Board, President, Chief Executive Officer, Founder
Co-Chairman of the Board, President, Chief Executive Officer, Founder
688.09K
+0.00%
Dr. Andrew J. Murphy, Ph.D.
Dr. Andrew J. Murphy, Ph.D.
Executive Vice President - Research
Executive Vice President - Research
52.21K
+0.06%
Mr. Joseph J. LaRosa
Mr. Joseph J. LaRosa
Executive Vice President, General Counsel, Secretary
Executive Vice President, General Counsel, Secretary
42.31K
-5.98%
Mr. Daniel P. Van Plew
Mr. Daniel P. Van Plew
Executive Vice President, General Manager - Industrial Operations and Product Supply
Executive Vice President, General Manager - Industrial Operations and Product Supply
35.18K
+0.02%
Mr. George L. Sing
Mr. George L. Sing
Independent Director
Independent Director
33.07K
+0.02%
Perguntas frequentes
Quem são os cinco principais acionistas de Regeneron Pharmaceuticals Inc?
Os cinco principais acionistas de Regeneron Pharmaceuticals Inc são: Dr. George D. Yancopoulos, M.D., Ph.D
Quantas instituições possuem ações da Regeneron Pharmaceuticals Inc (REGN)?
Em 2026Q1, 2806 instituições possuíam ações da Regeneron Pharmaceuticals Inc, com valor de mercado aproximado de 94.67M, representando 91.89% do total de ações. Em comparação com 2025Q4, a participação institucional aumentou em -1673066.00.
Qual é a maior fonte de receita da Regeneron Pharmaceuticals Inc?
Em 2026Q1, o segmento de negócios Sanofi gerou a maior receita para Regeneron Pharmaceuticals Inc, totalizando 5.88B e representando 41.02% da receita total.
